Segment Information

3 Months Ended

Mar. 31, 2019

Segment Information

Segment Information

12. Segment Information

Prior to the merger with Napo, the Company managed its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company reorganized its segments to reflect the change in the organizational structure resulting from the merger with Napo. Post-merger, the Company manages its operations through two reportable segments—human health and animal health. The human health segment is focused on developing and commercializing human products and the ongoing commercialization of Mytesi™, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals.

The Company's reportable segments net revenues and net loss consisted of:

	Three Months Ended
	March 31,
	2019		2018
		(unaudited)
Revenue from external customers
Human Health	$	1,543,121	$	583,269
Animal Health		46,612		43,698
Consolidated Totals	$	1,589,733	$	626,967
Segment profit (loss)
Human Health	$	(5,511,092)	$	(2,899,306)
Animal Health		(2,792,779)		(2,797,331)
Consolidated Totals	$	(8,303,871)	$	(5,696,637)